Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants
|ClinicalTrials.gov Identifier: NCT00308412|
Recruitment Status : Completed
First Posted : March 29, 2006
Last Update Posted : July 16, 2010
|Condition or disease||Intervention/treatment||Phase|
|Paramyxoviridae Infections Virus Diseases||Biological: rHPIV3cp45 Biological: Placebo||Phase 1|
HPIV type 3 (HPIV3) ranks second only to respiratory syncytial virus as the most important cause of bronchiolitis and pneumonia in infants less than 6 months of age. HPIV3 can cause severe disease in the first 2 years of life and is responsible for 11% of hospitalizations for respiratory diseases in children. This study will evaluate the safety and immunogenicity of a live recombinant attenuated intranasal HPIV3 vaccine, rHPIV3cp45.
This study will last for a maximum of 180 days. Infants will be enrolled into one of two study groups, Group 1 or Group 2. Depending on the study location, groups will enroll either sequentially or concurrently. Within each group, infants will be randomly assigned to receive 2 immunizations of rHPIV3cp45 or placebo. Immunizations will be given as nose drops. Immunizations will be given at study entry and approximately 4 to 10 weeks after study entry.
On the day of immunization, a physical exam, vital signs measurement, blood collection, and medical history will occur. Infants will be observed for 15 minutes after immunization for any immediate adverse effects. Parents or guardians will be given a thermometer to take with them and will be instructed on how to take their infant's temperature. They will be given the study schedule and will need to provide contact phone numbers so study personnel can contact them by phone during the days after immunization. Parents and guardians will be contacted by telephone on days without study visits, from Day 1 to Day 19 and on Day 180 after immunization, and asked about any illnesses or adverse effects they have observed in their immunized infants.
Parents or guardians will need to record their infant's temperature daily for at least the 17 days immediately following immunization. During this 17-day period, there will be at least 6 study visits associated with each immunization; visits will occur on the day of immunization and approximately 3, 7, 10, 14, and 17 days after immunization. At all study visits, infants will undergo a physical exam and vital signs measurement. Group 1 participants will also undergo a nasal wash for a viral culture. There will be additional follow-up visits occurring sometime between 28 and 70 days after the first dose and 28 to 35 days after the second dose; blood collection will occur at the follow-up visits. Additional visits may be required on selected days during the month after immunization. Infants who experience illness or side effects may be asked to return to the clinic for examination. Parents or guardians will be made aware of whether their infant received the HPIV vaccine or placebo 18 days after the second immunization or in the event of a lower respiratory tract illness.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||45 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age, and to HPIV3 Seronegative Infants and Children 6 to 36 Months of Age|
|Study Start Date :||June 2006|
|Actual Primary Completion Date :||April 2010|
|Actual Study Completion Date :||April 2010|
Two 10^5 PFU doses of rHPIV3cp45 vaccine given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
Placebo for rHPIV3cp45 vaccine is 1X L-15.
Placebo Comparator: 2
Two placebo vaccinations given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
Placebo for rHPIV3cp45 vaccine
- Frequency of vaccine-related reactogenicity events (REs) that occur during the acute monitoring phase of the study [ Time Frame: For 17 days after each dose ]
- Proportion of infants that develop fourfold or greater rises in hemagglutination-inhibition (HAI) antibody titer following two doses of vaccine [ Time Frame: Throughout study ]
- For the subset of infants enrolled in group 1 of the study (n=24), quantifying the amount of vaccine virus shed by each recipient [ Time Frame: Throughout study ]
- Assessment of the immunogenicity of a second dose of vaccine and the protection of the first dose against reinfection with the second dose [ Time Frame: Throughout study ]
- Determination of the number of vaccinated infants infected with rHPIV3cp45 [ Time Frame: Throughout study ]
- Determination of the number of vaccinated subjects infected with a second dose of rHPIV3cp45 vaccine [ Time Frame: Throughout study ]
- Determination of the phenotypic stability of vaccine virus shed [ Time Frame: Throughout study ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00308412
|United States, Maryland|
|Center for Immunization Research, Johns Hopkins University|
|Baltimore, Maryland, United States, 21205|
|Principal Investigator:||Ruth A. Karron, MD||Johns Hopkins Bloomberg School of Public Health|